Biblio

Author Title [ Type

] Year

Filters: Author is Hu, Jianda [Clear All Filters]

Journal Article

Yang T, Lin Q, Ren J, Chen P, Yuan X, Luo X, Liu T, Zheng J, Zheng Z, Zheng X, et al. A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget. 2016.

Chen Q, Zhang Y, Zhu H, Yuan X, Luo X, Wu X, Chen S, Chen Y, Xu J, Issa HAlly, et al. Bone marrow mesenchymal stem cells alleviate the daunorubicin-induced subacute myocardial injury in rats through inhibiting infiltration of T lymphocytes and antigen-presenting cells. Biomed Pharmacother. 2019;121:109157.

Huang H, Liu M, Ren J, Hu J, Lin S, Li D, Huang W, Chen S, Yang T, Wu X. Can Published Population Pharmacokinetic Models of Busulfan be used for Individualized Dosing in Chinese pediatric patients undergoing Hematopoietic Stem Cell Transplantation: An External Evaluation. J Clin Pharmacol. 2021.

Luo L, Chen Y, Wu Z, Huang Y, Lu L, Li J, Zheng X, Nie C, Chen R, Lin W, et al. Clinical characteristics, genetic alterations, and prognosis of adult T-cell leukemia/lymphoma: an 11-year multicenter retrospective study in China. Am J Cancer Res. 2024;14(4):1649-1661.

Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024.

Zhang Y, Zheng H, Ren J, Luo X, Zheng Z, Zheng J, Zheng X, Chen Y, Chen Z, Hu J, et al. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic le. Hematol Oncol. 2021.

Chen Y, Zheng J, Weng Y, Wu Z, Luo X, Qiu Y, Lin Y, Hu J, Wu Y. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia. Ann Hematol. 2024.

Chen Y, Huang X, Qiu H, Cheng L, Yu Y, Ma X, Feng S, Li Q, Wu D, Huang W, et al. Physicians' knowledge of invasive fungal disease in China. Mycoses. 2023.

Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.

Ren J, Lin K, Xu J, Lu Q, Luo Y, Lin C, Lu J, Weng Y, Zhang Y, Chen Z, et al. When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research. Clin Transplant. 2023:e15195.